PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers-Reference-Cited by-同舟云学术

PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers

Published:2017-03-22 Issue:4 Volume:40 Page:243-254
ISSN:0160-9289
Container-title:Clinical Cardiology
language:en
Short-container-title:Clin Cardiol

Author:

Baum Seth J.¹^ORCID,Toth Peter P.²,Underberg James A.³,Jellinger Paul⁴,Ross Joyce⁵,Wilemon Katherine⁶

Affiliation:

1. Department of Integrated Medical Sciences, Charles E. Schmidt College of MedicineFlorida Atlantic University Boca Raton Florida

2. CGH Medical Center, Sterling, Illinois, and Ciccarone Center for the Prevention of Heart DiseaseJohns Hopkins University School of Medicine Baltimore Maryland

3. Center for the Prevention of Cardiovascular Disease at New York University Langone Medical Center New York New York

4. Center for Diabetes and Endocrine CareFt. Lauderdale, Florida, and University of Miami Miller School of Medicine Miami Florida

5. University of Pennsylvania Health System Philadelphia Pennsylvania

6. The Familial Hypercholesterolemia Foundation Pasadena California

Funder

Amgen and Sanofi/Regeneron

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/clc.22713

Reference65 articles.

1. Praluent prescribing information. Sanofi US and Regeneron Pharmaceuticals.https://www.praluent.com/what‐is‐praluent?moc=pluco25009ps&utm_source=google&utm_medium=cpc&utm_campaign=2016_G_DTC_Branded&utm_content=Drug%20Information_Praluent%20Information_E&utm_term=praluent%20pi&gclid=CPHag_ncq9ECFdRtgQodDhUNNA&gclsrc=ds. Accessed January 5 2017

2. Repatha Prescribing Information. Amgen Inc.https://www.repatha.com/?WT.z_co=A&WT.z_in=LDL&WT.z_ch=PDS&WT.z_st=Site1&WT.z_mt=BM&WT.z_pdskw=rapatha&WT.z_se=G&WT.srch=1&WT.z_prm=Branded%202016_Misspellings%20Broad&WT.mc_id=A_LDL_PDS_G_Branded%202016_Misspellings%20Broad_BM_rapatha. Accessed January 5 2017.

3. The doctor's dilemma: Challenges in the diagnosis and care of homozygous familial hypercholesterolemia

4. PCSK9 inhibitors: payer dynamics. Symphony Health Solutions website.http://science.sciencemag.org/content/232/4746/34.long

5. Data from the FH Foundation's Patient Access Survey for FH Optimal Care for the US (FOCUS)2016. Unpublished document. FOCUS Registry FH Foundation Pasadena CA.

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study;American Journal of Preventive Cardiology;2024-03

2. A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates;npj Vaccines;2023-09-28

3. Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients;Circulation: Cardiovascular Quality and Outcomes;2023-08

4. A Virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in Non-Human Primates;2023-05-15

5. President's page: The re-emergence of prevention in the forefront of cardiology;American Journal of Preventive Cardiology;2023-03